Mind Medicine (MindMed) Inc.

Q1 2026 research and development expenses were $41.5 million, up from $23.4 million in Q1 2025, driven mainly by $15.2 million higher DT120 program costs, $3.2 million higher internal personnel costs, and $0.3 million higher DT402 costs. General and administrative expenses were $17.7 million versus $8.8 million a year ago, reflecting higher stock-based compensation, personnel, commercial preparedness, corporate/government affairs, and legal/patent costs. Net loss was $77.1 million versus $23.3 million in Q1 2025, including a $20 million impact from changes in the fair value of 2022 USD financing warrants tied to the share price moving from $13.39 to $18.90. The company ended Q1 with $373.4 million in cash, cash equivalents and investments and said that provides runway through multiple anticipated clinical readouts and into 2028. No quarterly revenue or EPS figures were provided in the transcript. Forward-looking timing: Emerge top-line data is expected later this quarter, Voyage early in Q3, Panorama late in Q3, and Haven in PTSD is planned for 2027.

Rob Barrow framed the quarter as the start of a pivotal year and emphasized disciplined execution ahead of multiple inflection points. He said the company is moving as efficiently as possible toward an NDA, subject to positive pivotal data, and highlighted a constructive working relationship with FDA enabled by breakthrough therapy designation in GAD. His tone was confident and forward-looking, repeatedly stressing that DT120 ODT could be a best-in-class candidate across depression, anxiety, and potentially PTSD.

Brandi Roberts highlighted that the company entered 2026 with enough financial flexibility to accelerate Phase III execution, NDA preparation, market access work, and commercial readiness. She cited Q1 R&D of $41.5 million and G&A of $17.7 million, both higher year over year because of intentional investment in development and organizational scaling. She also noted the $77.1 million net loss was affected by a $20 million non-cash warrant revaluation tied to the share price increase, and reiterated the $373.4 million quarter-end cash balance and runway into 2028.

Analysts focused on safety exposure, retreatment data, REMS/monitoring requirements, placebo response, PTSD study design, filing strategy, and commercialization capacity. Management said it feels comfortable with the safety exposure available at filing, including single-dose and longer-term data, and that Part B follow-up through up to a year should help characterize retreatment patterns and inform labeling. On monitoring, the company said it is building evidence to support single-monitor use in the real world; on placebo response, it expects Phase III design features like lower allocation ratios and Part B retention to reduce placebo effects versus Phase II. Management also said GAD and MDD filing timing may be concurrent or sequential depending on data and FDA discussions, and argued that current clinic capacity is already ample, with little need for major new infrastructure.